Table 4.
Relationship between allelic loss at the BRCA1 gene locus and clinicopathological characteristics
| Characteristic | Informative tumours | With LOH (%) | Without LOH (%) | p Value |
| Patients (n) | 244 | 97 (39.8) | 147 (60.2) | — |
| Age (y)* | 70 (11) | 71 (11) | 70 (10) | — |
| Sex | ||||
| Male | 146 (60) | 58 (39.7) | 88 (60.2) | |
| Female | 98 (40) | 39 (39.7) | 59 (60.3) | 0.84 |
| Tumour side | ||||
| Right | 55 (22.5) | 18 (32.7) | 37 (67.3) | |
| Left | 100 (41) | 45 (45) | 55 (55) | |
| Rectum | 89 (36.5) | 34 (38.3) | 55 (61.7) | 0.30 |
| Stage | ||||
| I | 30 (12.3) | 11 (36.7) | 19 (63.3) | |
| II | 102 (41.8) | 36 (35.3) | 66 (64.7) | |
| III | 94 (38.5) | 40 (42.6) | 54 (57.4) | |
| IV | 18 (7.4) | 10 (55.6) | 8 (44.4) | 0.37 |
| Vascular invasion | ||||
| Yes | 118 (48.3) | 46 (39) | 72 (61) | |
| No | 126 (51.7) | 51 (40.5) | 75 (59.5) | 0.91 |
| Polyps | ||||
| + | 75 (30.8) | 29 (39) | 46 (61) | |
| − | 169 (69.2) | 69 (40.5) | 100 (59.5) | 0.81 |
| CEA | ||||
| 0–5 ng/ml | 113 (46.3) | 44 (40) | 69 (60) | |
| >5 ng/ml | 46 (18.9) | 18 (39) | 28 (61) | 0.94 |
| Unknown | 85 (34.8) | 35 (40) | 50 (60) | |
| Lymph node metastases | ||||
| Negative | 137 (56.1) | 53 (38.7) | 84 (61.3) | |
| 1–3 | 71 (29.1) | 30 (42.3) | 41 (57.7) | 0.87 |
| ⩾4 | 36 (14.8) | 14 (38.9) | 22 (61.1) | |
| Tumour differentiation | ||||
| Well | 76 (31.1) | 27 (35.5) | 49 (64.5) | |
| Moderate | 124 (50.8) | 49 (39.5) | 75 (60.5) | 0.42 |
| Poor | 44 (18.1) | 21 (47.7) | 23 (52.3) | |
*Values are median (SEM). All other values are number (%).
LOH, loss of heterozygosity; CEA, carcinoembryonic antigen.